On Tuesday, Centessa Pharma ADR earned an upgrade to its Relative Strength (RS) Rating, from 88 to 92.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 at the beginning of a new climb.
How To Use Stock Charts To Stay Profitable And Protected
Centessa Pharma ADR is trying to complete a consolidation with a 19.09 entry. See if it can clear the breakout price in volume at least 40% higher than normal.
Centessa Pharma ADR posted 0% EPS growth last quarter. Sales rose -100%.
The company holds the No. 11 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
